Floatz logo

Botulinum Toxin Type B

Tumor

Georgetown UniversityPhase 4 / ApprovedDormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
89/ 100

Competitive context

928 Active assets in the Tumor cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Bxcl501
Medical College of Wisconsin
Phase 4BB
Relatlimab
Bristol-Myers Squibb
Phase 2BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB

View all 50 →

Same molecule, other indications

Botulinum Toxin Type B is also rated in:

SialorrheaDormant
BB
Indicative ·
67 / 100
View asset →
stroke disorderDormant
BB
Indicative ·
65 / 100
View asset →
brain injuryDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →